Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective
Andy Pike, Beth Williamson, Stephanie Harlfinger, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 10, pp. 1793-1800
Closed Access | Times Cited: 157

Showing 1-25 of 157 citing articles:

Advancing targeted protein degradation for cancer therapy
Brandon Dale, Meng Cheng, Kwang‐Su Park, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 638-654
Open Access | Times Cited: 400
Protein degraders enter the clinic — a new approach to cancer therapy
Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 265-278
Closed Access | Times Cited: 284
The PROTACtable genome
Melanie Schneider, Chris J. Radoux, Andrew Hercules, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 10, pp. 789-797
Closed Access | Times Cited: 161
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 148
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2576-2607
Closed Access | Times Cited: 131
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
Christiane Kofink, Nicole Trainor, Barbara Mair, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 131
Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 122
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
Yu Chen, Ira Tandon, William J. Heelan, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 13, pp. 5330-5350
Open Access | Times Cited: 120
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2534-2575
Closed Access | Times Cited: 113
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 112
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
Charles E. Hendrick, Jeff R. Jorgensen, Charu Chaudhry, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 7, pp. 1182-1190
Open Access | Times Cited: 88
Degrader-antibody conjugates
Peter S. Dragovich
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3886-3897
Closed Access | Times Cited: 76
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 73
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 69
Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13029-13040
Open Access | Times Cited: 66
Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 56
Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection
Daniel H. O’Donovan, Claudia De Fusco, Lara Kuhnke, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2347-2360
Closed Access | Times Cited: 49
Delivering on the promise of protein degraders
Matthew N. O’Brien, Suman Luthra, Matthew F. Brown, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 5, pp. 410-427
Closed Access | Times Cited: 48
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 42
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Yuan Fang, Shuhang Wang, Songzhe Han, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 303-317
Open Access | Times Cited: 38
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Exploring the chemical space of orally bioavailable PROTACs
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 12
Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies
Paul D. Leeson, A. Patrícia Bento, Anna Gaulton, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 11, pp. 7210-7230
Open Access | Times Cited: 78
The rise and rise of protein degradation: Opportunities and challenges ahead
Scott J. Hughes, Andrea Testa, Nicola Thompson, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 12, pp. 2889-2897
Open Access | Times Cited: 57
Discovery solubility measurement and assessment of small molecules with drug development in mind
Jaclyn A. Barrett, Wenzhan Yang, Suzanne Skolnik, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 5, pp. 1315-1325
Closed Access | Times Cited: 43
Page 1 - Next Page

Scroll to top